ALCJ — Crossject SA Share News
0.000.00%
Last trade - 00:00Brief: Crossject Signs A Geographic Extension Of Zepizure Commercialization Agreement In Europe
Brief: Crossject FY Operating Income Up At EUR 12.82 Mln
Brief: Crossject Announces Contract Of Up To $155 Mln With BARDA
Brief: Crossject Engages Syneos Health For U.S. Commercial Launch Of Zepizure
Brief: Crossject Signs Zepizure® Commercialization Agreement For Northern Europe
Brief: Crossject Reports H1 Operating Income Up At EUR 7.9 Million
Brief: Crossject Signs New Licensing Agreement On Zeneo® Midazolam Epilepsy Rescue Therapy With Aft Pharmaceuticals For Australia & New Zealand
Brief: Crossject: End-Dec Cash Of EUR 8 mln
Crossject: 2022 Annual Results
Crossject: Résultats annuels 2022
Brief: Crossject Announces Successful Completion Of Final Validation Study Of Zeneo Midazolam
Brief: Crossject Announces Results Of Exercise Of Warrants
Brief: Crossject: First Injections Of ZENEO Midazolam For Clinical Bioequivalence Study
Brief: Crossject FY Operating Loss Widens To EUR 10.7 Mln
Brief: Crossject Raises EUR 12 Mln Financing
Brief: Crossject H1 Operating Loss At 5.6 Million Euros
Brief: Crossject Anticipates Additional Cash Flow Contributions In 2020
Brief: Crossject End-Dec Operating Loss Narrows To 8.6 Million Euros
Brief: Crossject Raises 5.7 Million Euros Via Convertible Bond Issue